We are live on !
Find out more
CHI Advisors Portfolio holdings
AUM
$252M
Turnover
25.81%
1-Year Est. Return
56.99%
This Fund
S&P 500
This Quarter Est. Return
-7.97%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$252M
AUM Growth
-$77.3M
(-23%)
Cap. Flow
+$25.4M
Cap. Flow % of AUM
Cap. Flow %
10.07%
Top 10 Holdings %
Top 10 Hldgs %
81.34%
Holding
31
New
5
Increased
9
Reduced
8
Closed
3
Avg Time Held
Equity + Options
1.6
years
Top 10 Avg Time Held
Equity + Options
1.2
years
Top 20 Avg Time Held
Equity + Options
1.6
years
Avg Time Held Equity only
1.7
years
Top 10 Avg Time Held Equity only
1.2
years
Top 20 Avg Time Held Equity only
1.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
|
+$62.6M |
| 2 |
Mineralys Therapeutics
MLYS
|
+$7.41M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
+$5.15M |
| 4 |
Blueprint Medicines
BPMC
|
+$4.96M |
| 5 |
Sagimet Biosciences
SGMT
|
+$4.64M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$46.9M |
| 2 |
ACELYRIN
SLRN
|
+$8.51M |
| 3 |
Disc Medicine
IRON
|
+$5.01M |
| 4 |
Pliant Therapeutics
PLRX
|
+$1.78M |
| 5 |
Direxion Daily S&P Biotech Bear 3X ETF
LABD
|
+$1.62M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.08% |
| 2 | Miscellaneous | 1.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Precision BioSciences
DTIL
$181M
| $207K | 0.08% |
20,221
-33,231
| -62% | -$511K |
2019 Q3
16 quarters
|
|
27
CALL
DELISTED
Repare Therapeutics
RPTX
| $158K | 0.06% |
+50,000
| New | +$516K |
2023 Q3
0 quarters
|
|
|
28
CALL
Pliant Therapeutics
PLRX
$56.5M
| $55K | 0.02% |
137,500
+7,200
| +6% | +$125K |
2023 Q2
1 quarter
|
|
29
Corvus Pharmaceuticals
CRVS
$861M
| – | – |
-200,000
| Closed | -$458K | – |
|
30
DELISTED
HOOKIPA Pharma
HOOK
| – | – |
-78,874
| Closed | -$694K | – |
|
|
VECT
31
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| – | – |
-2,782,756
| Closed | -$46.9M | – |
|
Similar funds
SC
T
IAM
CHI Advisors's Q3 2023 Portfolio in Review
As of Q3 2023, CHI Advisors held 31 positions worth $252M, down 23% from $330M the previous quarter. Its ten largest holdings account for 81% of the portfolio.
CHI Advisors deployed $25.4M of net new capital in Q3 2023, opening 5 new positions and adding to 9 existing holdings. Its largest new stake was Mineralys Therapeutics: 568,379 shares worth $5.41M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was ACELYRIN, an estimated $8.51M trimmed.
- CHI Advisors's largest Q3 2023 buy was Mineralys Therapeutics: 568,379 shares worth $5.41M.
- CHI Advisors added most to Orchard Therapeutics plc American Depositary Shares in Q3 2023, an estimated $62.6M increase.
- CHI Advisors's biggest Q3 2023 reduction was ACELYRIN, cutting an estimated $8.51M.
- CHI Advisors fully exited VectivBio Holding AG Ordinary Shares in Q3 2023, selling an estimated $46.9M.
- CHI Advisors's ten largest holdings make up 81% of its $252M portfolio in Q3 2023.
- CHI Advisors opened 5 new positions and closed 3 in Q3 2023.
- CHI Advisors's portfolio value fell 23% quarter-over-quarter to $252M.
Based on CHI Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.